Effect of an Indigenously Developed Probiotic Enhanced Prebiotic A Synbiotic Therapy in Reducing Uremic Toxins of Patients with Chronic Kidney Disease Stage 3 And 4

Abstract

Lactic acid bacteria isolated from a synbiotic complex show promise in reducing the levels of key nephrovascular toxins in individuals with chronic kidney disease CKD Patients with CKD often exhibit an imbalance in bowel aerobic and anaerobic bacteria with an increase in uremic toxin producing aerobic bacteria and a decrease in beneficial anaerobic bacteria such as bifidobacteria and lactobacillus which can serve as probiotics High quality intervention trials investigating this novel approach in treating uremic toxins in patients with CKD are lacking This study aims to evaluate the efficacy of an indigenously developed synbiotic complex pro and prebiotic combination in targeting the clearance of uremic toxins specifically indoxyl sulfate Materials and Methods Forty patients with CKD stages 3 and 4 were enrolled in the study and administered a daily dose of 100 ml of synbiotic complex for three months Forty CKD patients on routine medical treatment were included as controls Glomerular filtration rate creatinine blood urea nitrogen levels and indoxyl sulfate were set as outcome parameters Results Analysis of blood urea nitrogen creatinine and indoxyl sulfate concentrations revealed a significant p less than 0 point 01 reduction in participants treated with the 100 ml dose of symbiotic complex compared to baseline measurements Conclusion Urea and indoxyl sulfate concentrations are important markers of kidney function and can have systemic toxic effects Regular use of synbiotics comprising probiotics and prebiotics may help delay the progression of kidney damage and potentially delay the need for dialysis newline